Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Repurposing of drugs for Covid-19: a systematic review and meta-analysis

Pinky Kotecha, Alexander Light, Enrico Checcucci, Daniele Amparore, Cristian Fiori, Francesco Porpiglia, Prokar Dasgupta, Oussama Elhage
doi: https://doi.org/10.1101/2020.06.07.20124677
Pinky Kotecha
1Faculty of Life Science & Medicine, King’s College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Light
1Faculty of Life Science & Medicine, King’s College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrico Checcucci
2Department of Oncology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano (Turin), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniele Amparore
2Department of Oncology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano (Turin), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristian Fiori
2Department of Oncology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano (Turin), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Porpiglia
2Department of Oncology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano (Turin), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prokar Dasgupta
1Faculty of Life Science & Medicine, King’s College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Prokar.dasgupta@kcl.ac.uk
Oussama Elhage
1Faculty of Life Science & Medicine, King’s College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective The aim of this systematic review is to evaluate the data currently available regarding the repurposing of different drugs for Covid-19 treatment. Participants with suspected or diagnosed Covid-19 will be included. The interventions being considered are drugs being repurposed, and comparators will include standard of care treatment or placebo.

Methods We searched Ovid-MEDLINE, EMBASE, Cochrane library, clinical trial registration site in the UK(NIHR), Europe (clinicaltrialsregister.eu), US (ClinicalTrials.gov) and internationally (isrctn.com), and reviewed the reference lists of articles for eligible articles published up to April 22, 2020. All studies in English that evaluated the efficacy of the listed drugs were included. Cochrane RoB 2.0 and ROBINS-I tool were used to assess study quality. This systematic review adheres to the PRISMA guidelines. The protocol is available at PROSPERO (CRD42020180915).

Results From 708 identified studies or clinical trials, 16 studies and 16 case reports met our eligibility criteria. Of these, 6 were randomized controlled trials (763 patients), 7 cohort studies (321 patients) and 3 case series (191 patients). Chloroquine (CQ) had a 100% discharge rate compared to 50% with lopinavir-ritonavir at day 14, however a trial has recommended against a high dosage due to cardiotoxic events. Hydroxychloroquine (HCQ) has shown no significant improvement in negative seroconversion rate which is also seen in our meta-analysis (p=0.68). Adverse events with HCQ have a significant difference compared to the control group (p=0.001). Lopinavir-ritonavir has shown no improvement in time to clinical improvement which is seen in our meta-analyses (p=0.1). Remdesivir has shown no significant improvement in time to clinical improvement but this trial had insufficient power.

Discussion Due to the paucity in evidence, it is difficult to establish the efficacy of these drugs in the treatment of Covid-19 as currently there is no significant clinical effectiveness of the repurposed drugs. Further large clinical trials are required to achieve more reliable findings. A risk-benefit analysis is required on an individual basis to weigh out the potential improvement in clinical outcome and viral load reduction compared to the risks of the adverse events. (1-16)

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

none

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

no irb approval needed

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All the data included are available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 09, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Repurposing of drugs for Covid-19: a systematic review and meta-analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Repurposing of drugs for Covid-19: a systematic review and meta-analysis
Pinky Kotecha, Alexander Light, Enrico Checcucci, Daniele Amparore, Cristian Fiori, Francesco Porpiglia, Prokar Dasgupta, Oussama Elhage
medRxiv 2020.06.07.20124677; doi: https://doi.org/10.1101/2020.06.07.20124677
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Repurposing of drugs for Covid-19: a systematic review and meta-analysis
Pinky Kotecha, Alexander Light, Enrico Checcucci, Daniele Amparore, Cristian Fiori, Francesco Porpiglia, Prokar Dasgupta, Oussama Elhage
medRxiv 2020.06.07.20124677; doi: https://doi.org/10.1101/2020.06.07.20124677

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (202)
  • Anesthesia (54)
  • Cardiovascular Medicine (495)
  • Dentistry and Oral Medicine (91)
  • Dermatology (57)
  • Emergency Medicine (170)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (217)
  • Epidemiology (5744)
  • Forensic Medicine (3)
  • Gastroenterology (219)
  • Genetic and Genomic Medicine (879)
  • Geriatric Medicine (89)
  • Health Economics (233)
  • Health Informatics (775)
  • Health Policy (399)
  • Health Systems and Quality Improvement (256)
  • Hematology (105)
  • HIV/AIDS (186)
  • Infectious Diseases (except HIV/AIDS) (6569)
  • Intensive Care and Critical Care Medicine (395)
  • Medical Education (119)
  • Medical Ethics (28)
  • Nephrology (94)
  • Neurology (856)
  • Nursing (45)
  • Nutrition (143)
  • Obstetrics and Gynecology (166)
  • Occupational and Environmental Health (264)
  • Oncology (520)
  • Ophthalmology (168)
  • Orthopedics (44)
  • Otolaryngology (107)
  • Pain Medicine (48)
  • Palliative Medicine (22)
  • Pathology (150)
  • Pediatrics (256)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (116)
  • Psychiatry and Clinical Psychology (988)
  • Public and Global Health (2262)
  • Radiology and Imaging (379)
  • Rehabilitation Medicine and Physical Therapy (175)
  • Respiratory Medicine (313)
  • Rheumatology (109)
  • Sexual and Reproductive Health (83)
  • Sports Medicine (83)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)